SEPOY.net
No Result
View All Result
Sunday, July 20, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Researchers set sights on a new therapeutic target for aggressive breast cancer

Nicholas by Nicholas
October 25, 2022
in Health
0

Researchers at VCU Massey Cancer Center have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options.

READ ALSO

Hypertensive disorders in pregnancy linked to lower breastfeeding rates

Ancient viral DNA found to regulate human gene expression

Breast cancer is the second most common cancer in U.S. women, and triple-negative breast cancer (TNBC) is a more aggressive and deadly form of disease that accounts for 10-15% of all breast tumors.

TNBC grows and spreads more quickly than other breast tumors and is associated with worse patient outcomes, accounting for nearly one-third of all breast cancer-related deaths.

Additionally, TNBC affects Black women disproportionately: Black women die from TNBC at a significantly higher rate than white women despite being diagnosed at a younger age. Finding an effective therapy that works well in all patients would be an important step in addressing this disparity.

Through a comprehensive and cutting-edge genomic screening method known as CRISPR/CAS9 screening, Massey scientists -; led by Anthony Faber, Ph.D., and Jennifer Koblinski, Ph.D. -; were able to identify a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.

Previous research has shown that UBA1 inhibitors can have a positive impact in hematological cancers such as acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML). This study -; recently published in PNAS Nexus -; is the first to suggest that UBA1 inhibitors could be effective in TNBC. TAK-243 has been tested recently in early phase trials, paving the way for potential testing in TNBC patients.

“We found that the majority of TNBC cells in our study were uniformly susceptible to the antitumor effects of TAK-243,” said Koblinski, director of the Cancer Mouse Models Core and member of the Cancer Biology research program at Massey, as well as an associate professor of pathology at the VCU School of Medicine. “In addition to demonstrating this drug’s success at the local site of the primary breast cancer, our findings demonstrate that TAK-243 can also shrink tumors in various organs after the disease has spread.”

The researchers also determined that the c-MYC gene -; an important and infamously difficult drug target in TNBC -; can be harnessed to cooperate with TAK-243 to initiate a cellular stress response and enhance the drug’s ability to fight TNBC. This supports the notion that TAK-243 may be effective in high-cMYC-expressing TNBC, where c-MYC may serve as a biomarker for response to the drug.

Chemotherapy remains one of the few routinely utilized treatment options for TNBC, with variable patient responses and little efficacy.

“The implementation of targeted therapies -; drugs that target a specific genetic defect -; has been revolutionary in treating different cancers, including breast cancer,” said Faber, co-leader of the Developmental Therapeutics research program and Natalie N. and John R. Congdon, Sr. Endowed Chair in Cancer Research at Massey, as well as an associate professor in the Philips Institute for Oral Health Research at the VCU School of Dentistry.

However, the hormone receptors, estrogen receptors or human epidermal growth factor receptor 2 (HER2) that can be effectively targeted in breast cancer treatment are missing in TNBC, hence the name “triple-negative breast cancer.”

Genomic and clinical evidence suggests that the implementation of targeted therapies in the treatment of TNBC will require an expansion of potential targets. Our study may have identified a key and novel target for the development of new therapies.”


Anthony Faber, Ph.D., Massey Scientist

Faber added, “Importantly, as TNBC is a major disease of disparate outcomes between Black patients and white patients, we were able to harness the power of new breast cancer mouse models from Black TNBC patients that were developed by Dr. Koblinski’s group. Traditionally, these models have been underrepresented and are important new tools to identify effective therapies for Black patients. The most exciting part of the study was that we found TAK-243 was effective across these models, suggesting TAK-243 or other UBA1 inhibitors could be equally effective in all TNBC patients.”

The next steps of this research include exploring the use of TAK-243 in TNBC with the drug company that is developing it, and evaluating other targets in the UBA1 pathway that may also demonstrate efficacy.

Source:

Virginia Commonwealth University

Journal reference:

Jacob, S., et al. (2022) Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC models. PNAS Nexus. doi.org/10.1093/pnasnexus/pgac232.

Source

Tags: Breast CancerCancerCas9CRISPRDentistryEfficacyEnzymeGenomicLeukemiaMedical SchoolMedicinepHResearch

Related Posts

Hypertensive disorders in pregnancy linked to lower breastfeeding rates
Health

Hypertensive disorders in pregnancy linked to lower breastfeeding rates

July 19, 2025
Ancient viral DNA found to regulate human gene expression
Health

Ancient viral DNA found to regulate human gene expression

July 19, 2025
Agricultural dust exposure may pose significant risks to gut health
Health

Agricultural dust exposure may pose significant risks to gut health

July 19, 2025
Heart-healthy habits can improve overall physical and psychological well-being
Health

Heart-healthy habits can improve overall physical and psychological well-being

July 19, 2025
New insights into diagnosis and treatment of tibial tubercle avulsion fractures in young athletes
Health

New insights into diagnosis and treatment of tibial tubercle avulsion fractures in young athletes

July 19, 2025
Study reveals complex patterns of burden and survival among people with digestive system cancers in China
Health

Study reveals complex patterns of burden and survival among people with digestive system cancers in China

July 18, 2025
Next Post

UArizona researchers working on a less toxic treatment for deadly breast cancer

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • 15 Full Report Towns to locate Lost Appreciate in the Fl Maps and
  • Tagesordnungspunkt Verzeichnis casino 7bit sign up bonus Casinos Bejeweled dos Added bonus 2025
  • Idræt Vederlagsfri Husar S Luck Deluxe Online casino The Invisible Man Spilleautomat

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net